MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Crizotinib-d8
MCE 国际站:Crizotinib-d8
品牌:MedChemExpress (MCE)
货号:HY-50878S1
CAS:1523579-82-9
中文名称:克唑替尼-d8
Synonyms:PF-02341066-d8
存储条件:请将产品存放在分析证书上推荐的条件下。
运输条件:美国大陆的室温;其他地方可能有所不同。
产品活性:Crizotinib-d8 (PF-02341066-d8) 是氘代标记的 Crizotinib. Crizotinib (PF-02341066) 是一种具有口服活性的,ATP 竞争性的 ALK 和 c-Met 抑制剂,IC50 分别为 20 和 8 nM。在细胞的实验中,Crizotinib 抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化,IC50 分别为 24 和 11 nM。Crizotinib 也是 ROS1 抑制剂。Crizotinib 具有有效的肿瘤生长抑制作用。
生物活性:克唑替尼-d8 (PF-02341066-d8) 是氘标记的克唑替尼。克唑替尼 (PF-02341066) 是一种口服生物可利用的 ATP 竞争性 ALK 和 c-Met 抑制剂,IC50 分别为 20 nM 和 8 nM。克唑替尼可抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化,在细胞实验中 IC50 分别为 24 nM 和 11 nM。克唑替尼也是 ROS1 抑制剂。克唑替尼具有有效的肿瘤生长抑制作用[1][2][3]。
体外:氢、碳和其他元素的稳定重同位素已被掺入药物分子中,主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。
热销产品:5-Propargylamino-dCTP 
| 
Lirentelimab 
| 
Revdofilimab 
| 
YS-370 
| 
Gosuranemab 
| 
Homoeriodictyol 
| 
BRD7552 
| 
Canthaxanthin 
| 
γ-Cyclodextrin 
| 
YTHDF2, Human (His)
Trending products:Recombinant Proteins 
| 
Natural Products 
| 
Fluorescent Dye 
| 
PROTAC 
| 
Oligonucleotides
参考文献:
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019
53(2):211-216.
[2]. Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar
8(3):354-369.
[3]. Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1
75(21):4548-59.
[4]. Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28
7(349):ra102.
[5]. Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug
11(8):996-1006.
[6]. Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22
54(18):6342-63.
[7]. Cullinane C, et al. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug
52(8):1261-7
[8]. Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67(9), 4408-4417.
[9]. Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322.